Grey House Partners

Grey House Partners is a private venture capital and investment management firm operating through the Noetic Fund brand. The firm focuses on early-stage companies in mental health, wellbeing, biotech, digital health, medical devices, wellness, and related healthcare technologies. Its investment strategy emphasizes CNS-targeted therapeutics, psychedelic and non-psychedelic mental health treatments, and evidence-backed solutions intended to address root causes of illness, prevention, and resilience. Grey House Partners appears to be an investor rather than a drug developer, so it does not have an internal therapeutic pipeline in the conventional biotech sense.